Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 19/20 | 0.77 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16600915 | 0.87 | GRIN2B (1.00) | GRIN2BGRIN1 | |
| SCHEMBL16995702 | 0.87 | GRIN2B (1.00) | GRIN2BGRIN1 | |
| SCHEMBL30076209 | 0.87 | GRIN2B (1.00) | GRIN2BGRIN1 | |
| SCHEMBL20841792 | 0.85 | GRIN2B (0.78) | GRIN2BGRIN1 | |
| SCHEMBL18629698 | 0.83 | GRIN2B (0.79) | GRIN2B | |
| SCHEMBL20090887 | 0.81 | GRIN2B (0.50) | GRIN2BGRIN1ESR1ESR2 | |
| SCHEMBL18629458 | 0.81 | GRIN2B (0.74) | GRIN2B | |
| SCHEMBL18629327 | 0.81 | GRIN2B (0.82) | GRIN2B | |
| SCHEMBL18629286 | 0.80 | GRIN2B (0.52) | GRIN2BGRIN1 | |
| SCHEMBL20090860 | 0.80 | GRIN1 (0.78) | GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | CADENT THERAPEUTICS, INC (US) | 2021-09-14 | — | — | US | disclosed |
| US-20170071906-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | LUC THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071906-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRIN1 6/4885ESR1 1488/4885 |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRIN1 6/4885ESR1 1488/4885 |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRIN1 6/4885ESR1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.